CollPlant Biotechnologies (XTAE:CLGN) ROCE % : -61.62% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is CollPlant Biotechnologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CollPlant Biotechnologies's annualized ROCE % for the quarter that ended in Dec. 2023 was -61.62%.

CollPlant Biotechnologies ROCE % Historical Data

The historical data trend for CollPlant Biotechnologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CollPlant Biotechnologies ROCE % Chart

CollPlant Biotechnologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-110.48

-75.93

0.23

-41.26

-22.92

CollPlant Biotechnologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-51.32	-41.70	63.41	-49.95	-61.62

CollPlant Biotechnologies ROCE % Calculation

CollPlant Biotechnologies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-27.604	/	( ( (138.787 - 11.41)	+	(125.403 - 11.946) )	/ 2 )
	=	-27.604	/	( (127.377	+	113.457)	/ 2 )
	=	-27.604	/	120.417
	=	-22.92 %

CollPlant Biotechnologies's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-74.492	/	( ( (138.015 - 9.679)	+	(125.403 - 11.946) )	/ 2 )
	=	-74.492	/	( ( 128.336	+	113.457 )	/ 2 )
	=	-74.492	/	120.8965
	=	-61.62 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

CollPlant Biotechnologies (XTAE:CLGN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CollPlant Biotechnologies ROCE % Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

CollPlant Biotechnologies (XTAE:CLGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (XTAE:CLGN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CLGN:USA CPT:Germany

Address

4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104

Website

https://www.collplant.com

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The company's revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing.